Patents by Inventor Shaun R. Stauffer

Shaun R. Stauffer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • WDR5-MYC INHIBITORS
    Publication number: 20230022304
    Abstract: Substituted N-heteroaryl sulfonamide compounds inhibit WDR5-MYC interactions, and the compounds and their pharmaceutical compositions are useful for treating disorders and conditions in a subject such as cancer cell proliferation.
    Type: Application
    Filed: November 18, 2020
    Publication date: January 26, 2023
    Inventors: Selena Chacon Simon, Alex Waterson, Jonathan D. MacDonald, Stephen Fesik, Shaun R. Stauffer, William P. Tansey
  • WDR5 INHIBITORS AND MODULATORS
    Publication number: 20230012362
    Abstract: Isoquinolinone compounds and derivatives inhibit WDRS and associated protein-protein interactions, and the compounds and their pharmaceutical compositions are useful for treating disorders and conditions in a subject, such as cancer cell proliferation.
    Type: Application
    Filed: October 24, 2019
    Publication date: January 12, 2023
    Inventors: Taekyu Lee, Joseph R. Alvarado, Jianhua Tian, Kenneth M. Meyers, Changho Han, Jonathan J. Mills, Kevin B. Teuscher, Shaun R. Stauffer, Stephen W. Fesik
  • WDR5-MYC INHIBITORS
    Publication number: 20220289673
    Abstract: Substituted N-phenyl sulfonamide compounds inhibit WDR5-MYC interactions, and the compounds and their pharmaceutical compositions are useful for treating disorders and conditions in a subject, such as cancer cell proliferation.
    Type: Application
    Filed: July 29, 2020
    Publication date: September 15, 2022
    Inventors: William P. Tansey, Stephen W. Fesik, Shaun R. Stauffer, Alex G. Waterson, Changho Han, Joseph R. Alvarado, Jonathan D. MacDonald, Selena Chacon Simon, Sameer S. Nikhar, Alexey Kuznetsov
  • ALLOSTERIC ACTIVATORS OF THE ALPHA1A-ADRENERGIC RECEPTOR
    Publication number: 20220227717
    Abstract: The present invention relates to compounds that are activators of the Alpha1A-Adrenergic Receptor (?1A-AR) and methods of using such compounds: for treating neurological conditions, for cardio-protection, and for treating other conditions. In certain embodiments, the ?1A-AR activator compound is a compound of Formula I. In certain embodiments, the neurological condition is Alzheimer's disease, benign prostatic hyperplasia, memory loss, depression, or Parkinson's disease.
    Type: Application
    Filed: April 23, 2020
    Publication date: July 21, 2022
    Inventors: Dianne M. PEREZ, Shaun R. STAUFFER, Jonathan MACDONALD
  • WDR5 inhibitors and modulators
    Patent number: 10844044
    Abstract: Described are imino-azacycle-benzamide compounds that inhibit WDR5 and associated protein-protein interactions, pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating disorders and conditions in a subject.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: November 24, 2020
    Assignee: Vanderbilt University
    Inventors: Joseph R. Alvarado, Shaun R. Stauffer, Rocco D. Gogliotti, Changho Han, Kenneth M. Meyers, Jianhua Tian, Jonathan D. Macdonald, Stephen W. Fesik, Taekyu Lee
  • WDR5-MLL1 inhibitors and modulators
    Patent number: 10807959
    Abstract: Benzamides and picolinamides that are meta-substituted with imino-, guanidino-, or heterocycle-containing groups disrupt the WDR5-MLL1 protein-protein interaction, and have use in pharmaceutical compositions and in treating proliferative disorders and conditions in a subject, such as cancer.
    Type: Grant
    Filed: August 16, 2019
    Date of Patent: October 20, 2020
    Assignee: Vanderbilt University
    Inventors: Rocco D. Gogliotti, Shaun R. Stauffer, KyuOk Jeon, James M. Salovich, Jonathan D. Macdonald, Jonathan J. Mills, Kenneth M. Meyers, Joseph R. Alvarado, Changho Han, Stephen W. Fesik, Taekyu Lee
  • WDR5 INHIBITORS AND MODULATORS
    Publication number: 20200102288
    Abstract: Described are imino-azacycle-benzamide compounds compounds that inhibit WDR5 and associated protein-protein interactions, pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating disorders and conditions in a subject.
    Type: Application
    Filed: June 14, 2019
    Publication date: April 2, 2020
    Inventors: Joseph R. Alvarado, Shaun R. Stauffer, Rocco D. Gogliotti, Changho Han, Kenneth M. Meyers, Jianhua Tian, Jonathan D. Macdonald, Stephen W. Fesik, Taekyu Lee
  • WDR5-MLL1 INHIBITORS AND MODULATORS
    Publication number: 20200055824
    Abstract: Benzamides and picolinamides that are meta-substituted with imino-, guanidino-, or heterocycle-containing groups disrupt the WDR5-MLL1 protein-protein interaction, and have use in pharmaceutical compositions and in treating proliferative disorders and conditions in a subject, such as cancer.
    Type: Application
    Filed: August 16, 2019
    Publication date: February 20, 2020
    Inventors: Rocco D. Gogliotti, Shaun R. Stauffer, KyuOk Jeon, James M. Salovich, Jonathan D. Macdonald, Jonathan J. Mills, Kenneth M. Meyers, Joseph R. Alvarado, Changho Han, Stephen W. Fesik, Taekyu Lee
  • WDR5 inhibitors and modulators
    Patent number: 10501466
    Abstract: Described are N-(6-(6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)-2,3-dihydro-1H-inden-1-yl)benzamide and acetamide-containing compounds that inhibit WDR5 and associated protein-protein interactions, pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating disorders and conditions in a subject.
    Type: Grant
    Filed: September 19, 2018
    Date of Patent: December 10, 2019
    Assignee: Vanderbilt University
    Inventors: Stephen W. Fesik, Shaun R. Stauffer, James M. Salovich, William P. Tansey, Feng Wang, Jason Phan, Edward T. Olejniczak
  • SUBSTITUTED AND FUSED 6-MEMBERED PROTEASE ACTIVATED RECEPTOR 4 (PAR-4) ANTAGONISTS
    Publication number: 20190119300
    Abstract: Embodiments of the invention include compounds and compositions thereof to inhibit protease activated receptor-4. Also described are methods of preparation of compositions and methods for treating diseases related to thrombotic disorders by administration of the composition.
    Type: Application
    Filed: April 17, 2017
    Publication date: April 25, 2019
    Inventors: Heidi E. Hamm, Shaun R. Stauffer, Craig W. Lindsley, Matthew T. Duvernay, Kayla J. Temple
  • WDR5 INHIBITORS AND MODULATORS
    Publication number: 20190084988
    Abstract: Described are N-(6-(6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)-2,3-dihydro-1H-inden-1-yl)benzamide and acetamide-containing compounds that inhibit WDR5 and associated protein-protein interactions, pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating disorders and conditions in a subject.
    Type: Application
    Filed: September 19, 2018
    Publication date: March 21, 2019
    Inventors: Stephen W. Fesik, Shaun R. Stauffer, James M. Salovich, William P. Tansey, Feng Wang, Jason Phan, Edward T. Olejniczak
  • WDR5 inhibitors and modulators
    Patent number: 10160763
    Abstract: Described are compounds that disrupt the WDR5-MLL1 protein-protein interaction, pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating disorders and conditions in a subject.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: December 25, 2018
    Assignee: Vanderbilt University
    Inventors: Stephen W. Fesik, Shaun R. Stauffer, William P. Tansey, Edward T. Olejniczak, Jason Phan, Feng Wang, KyuOk Jeon, Rocco D. Gogliotti
  • Substituted 5-membered heterocyclic analogs as protease activated receptor 4 (PAR-4) antagonists
    Patent number: 9963466
    Abstract: Embodiments of the invention include compounds and compositions thereof to inhibit protease activated receptor-4. Also described are methods of preparation of compositions and methods for treating diseases related to thrombotic disorders by administration of the composition.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: May 8, 2018
    Assignee: Vanderbilt University
    Inventors: Heidi E. Hamm, Shaun R. Stauffer, Craig W. Lindsley, Matthew T. Duvernay, Kayla J. Temple
  • WDR5 INHIBITORS AND MODULATORS
    Publication number: 20180086767
    Abstract: Described are compounds that disrupt the WDR5-MLL1 protein-protein interaction, pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating disorders and conditions in a subject.
    Type: Application
    Filed: September 13, 2017
    Publication date: March 29, 2018
    Inventors: Stephen W. Fesik, Shaun R. Stauffer, William P. Tansey, Edward T. Olejniczak, Jason Phan, Feng Wang, KyuOk Jeon, Rocco D. Gogliotti
  • Substituted 5-Membered Heterocyclic Analogs as Protease Activated Receptor 4 (PAR-4) Antagonists
    Publication number: 20170253617
    Abstract: Embodiments of the invention include compounds and compositions thereof to inhibit protease activated receptor-4. Also described are methods of preparation of compositions and methods for treating diseases related to thrombotic disorders by administration of the composition.
    Type: Application
    Filed: March 7, 2017
    Publication date: September 7, 2017
    Inventors: Heidi E. Hamm, Shaun R. Stauffer, Craig W. Lindsley, Matthew T. Duvernay, Kayla J. Temple
  • Substituted 4-benzyl-3,4-dihydro-2-benzo[][1,4]oxazine-2-carboxamide analogs as positive allosteric modulators of muscarinic acetycholine receptor M1
    Patent number: 9708278
    Abstract: In one aspect, the invention relates to N-substituted 3,4-dihydro-benzo[£][1,4]oxazine-2-carboxamide analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor M1 (mAChR M1); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: November 18, 2014
    Date of Patent: July 18, 2017
    Assignee: Vanderbilt University
    Inventors: Craig W. Lindsley, P. Jeffrey Conn, Shaun R. Stauffer, Joseph D. Panarese
  • Substituted indoles as selective protease activated receptor 4 (PAR-4) antagonists
    Patent number: 9572794
    Abstract: Embodiments of the invention include substituted indole compounds and compositions thereof to inhibit protease activated receptor-4. Also described are methods of preparation of compositions and methods for treating diseases related to thrombotic disorders by administration of the composition.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: February 21, 2017
    Assignee: Vanderbilt University
    Inventors: Heidi E. Hamm, Shaun R. Stauffer, Craig W. Lindsley, Wandong Wen, Summer E. Young, Matthew T. Duvernay, Kayla J. Temple
  • SUBSTITUTED 4-BENZYL-3,4-DIHYDRO-2H-BENZO[B][1,4]OXAZINE-2CARBOXAMIDE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC ACETYCHOLINE RECEPTOR M1
    Publication number: 20170022173
    Abstract: In one aspect, the invention relates to N-substituted 3,4-dihydro-benzo[£][1,4]oxazine-2-carboxamide analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor M1 (mAChR M1); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: November 18, 2014
    Publication date: January 26, 2017
    Inventors: Craig W. Lindsley, P. Jeffrey Conn, Shaun R. Stauffer, Joseph D. Panarese
  • Substituted quinazolin-4(3H)-ones, pyrido[3,4-d]pyrimidin-4(3H)-ones, pyrido[3,2-d]pyrimidin-4(3H)-ones and pyrido[2,3-d]pyrimidin-4(3H)-ones as positive allosteric modulators of muscarinic acetycholine receptor M1
    Patent number: 9540371
    Abstract: In one aspect, the invention relates to 3-benzylquinazolin-4(3H)-one analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor M1 (mAChR M1); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: January 10, 2017
    Assignee: Vanderbilt University
    Inventors: Craig W. Lindsley, P. Jeffrey Conn, Shaun R. Stauffer, Joseph David Panarese
  • Substituted 1-benzylquinoxalin-2(1H)-one analogs as positive allosteric modulators of muscarinic acetylcholine receptor M1
    Patent number: 9527834
    Abstract: The invention relates to substituted 1-benzylquinoxalin-2(1H)-one analogs, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor M1 (mAChR M1); methods for making the compounds; pharmaceutical compositions; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: December 27, 2016
    Assignee: Vanderbilt University
    Inventors: Craig W. Lindsley, P. Jeffrey Conn, Shaun R. Stauffer, Joseph David Panarese